The macrophage activation marker sCD 163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background & Aims: Macrophage activation plays a key pathogenic role in experimental non‐alcoholic fatty liver disease (NAFLD) and contributes to the progression of steatohepatitis (NASH) and fibrosis. We studied macrophage activation in human NAFLD by measuring soluble (s)CD 163, a specific macrophage activation marker, hypothesizing that sCD 163 would be associated with the patients’ morphological disease grade. Furthermore, we investigated an association between sCD 163 and the apoptosis marker cytokeratin‐18 (CK‐18) to explore a link between macrophage activation and apoptosis. Methods: sCD 163 associations with biochemical and histological measures of NAFLD were investigated in two independent cohorts of 157 Australian and 174 Italian NAFLD patients, with liver biopsies graded for NAFLD severity, steatosis and fibrosis. sCD 163 and CK‐18 were measured by enzyme‐linked immunosorbent assay. Results: In both cohorts sCD 163 increased in parallel with the patients’ morphological disease grading, being independently associated with the Kleiner fibrosis score (P < 0.001). A high sCD 163 predicted advanced fibrosis {F ≥ 3; Australian cohort: area under receiver‐operating characteristics curve 0.77 [95% confidence interval (CI): 0.76–0.87], Italian cohort: 0.80 (95% CI: 0.72–0.88)}. In both groups, sCD 163 was independently associated with CK‐18 (P < 0.001). Conclusion: Soluble CD 163 reflecting macrophage activation is associated with morphological features of NAFLD suggesting their involvement in the pathogenesis of NAFLD, NASH and particularly fibrosis. An independent association between sCD 163 and cytokeratin‐18 suggests that apoptosis may contribute to macrophage activation in NAFLD/NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 1×
“Recent data indicate that fibrosis stage is the histological feature best associated with the long-term outcome of NAFLD (40, 41).”
BackgroundMacrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“Macrophages in the liver play a critical role in inflammation and fibrosis (1), including in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).”
BackgroundBugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
Self-citationStienstra, R., Saudale, F., Duval, C., Keshtkar, S., Groener, J. E. M., van Rooijen, N., Staels, B., Kersten, S., & Müller, M. (2010) · Hepatology · doi:10.1002/hep.23337 · Cited by 452 · cited 1×
“Together, these human data support a key role for hepatic macrophages in NAFLD/NASH pathogenesis as proposed by experimental studies (3, 4, 30).”
BackgroundTosello-Trampont, A.-C., Landes, S. G., Nguyen, V., Novobrantseva, T. I., & Hahn, Y. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417014 · Cited by 415
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
Turner, R. C., Holman, R. R., Matthews, D., Hockaday, T. D. R., & Peto, J. (1979) · Metabolism · doi:10.1016/0026-0495(79)90146-x · Cited by 388
Itoh, M., Kato, H., Suganami, T., Konuma, K., Marumoto, Y., Terai, S., Sakugawa, H., Kanai, S., Hamaguchi, M., Fukaishi, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082163 · Cited by 211 · cited 1×
“Along the same line, we observed a greater number of CD163-positive macrophages clustering into microgranulomas in the stained biopsies from patients with NASH similar to earlier studies (38, 39), and an association of sCD163 with the degree of hepatocyte ballooning and macrophage clustering.”
Result
Cited by
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Self-citationKrenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557
Liver Macrophages: Old Dogmas and New Insights
Guillot, A., & Tacke, F. (2019) · Hepatology Communications · doi:10.1002/hep4.1356 · Cited by 335
Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism
Lefere, S., & Tacke, F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.004 · Cited by 278
Metadata
- Authors
- Kazankov, K., Barrera, F., Møller, H. J., Rosso, C., Bugianesi, E., David, E., Ibrahim Kamal Jouness, R., Esmaili, S., Eslam, M., McLeod, D., Bibby, B. M., Vilstrup, H., George, J., & Grønbæk, H.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2016-05-12
- Volume
- 36
- Issue
- 10
- Pages
- 1549-1557
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2337435850
- Cited by
- 113
- References
- 9
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.